Vertex Announces Appointment of Jeffrey A. Chodakewitz, M.D., as Chief Medical Officer and Senior Vice President of Global

  Vertex Announces Appointment of Jeffrey A. Chodakewitz, M.D., as Chief
  Medical Officer and Senior Vice President of Global Medicines Development

Business Wire

BOSTON -- January 8, 2014

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) today announced the
appointment of Jeffrey A. Chodakewitz, M.D., as Chief Medical Officer and
Senior Vice President. Dr. Chodakewitz has more than 20 years of experience
leading global development organizations in the biopharmaceutical industry,
including roles as Senior Vice President of late-stage global development and
Vice President of early-stage development at Merck. As head of Vertex’s Global
Medicines Development and Medical Affairs department, he will oversee all
global clinical development programs, medical affairs and other related
functions. Following a planned transition period, Vertex’s current Chief
Medical Officer, Robert Kauffman, M.D., Ph.D., will retire from the company in
the second half of 2014. Dr. Kauffman served in senior roles in clinical
development during his more than 15 years at Vertex and has been Vertex’s
Chief Medical Officer since 2009.

“I’d like to thank Bob Kauffman for his many significant contributions to
Vertex and his unwavering commitment to bringing new medicines to people with
hepatitis C and cystic fibrosis,” said Jeffrey Leiden, M.D., Ph.D., Chairman,
President and Chief Executive Officer of Vertex. “As Bob transitions toward
his retirement from Vertex later this year, I am excited to welcome Jeff
Chodakewitz to our team. Jeff brings deep and broad experience in leading
successful development efforts for medicines across multiple diseases. His
experience will be invaluable to our current research and development efforts
in cystic fibrosis and other serious diseases.”

“I’ve been deeply impressed by Vertex’s innovative approach to developing new
medicines and the company’s ability to put science and patients at the core of
its business,” said Dr. Chodakewitz. “I look forward to joining the Vertex
team as we seek to help more people with cystic fibrosis as well as patients
with other serious diseases.”

Prior to joining Vertex, Dr. Chodakewitz spent over 20 years at Merck Research
Laboratories where he held multiple leadership roles in clinical pharmacology
and oversaw clinical development and program regulatory strategy. During his
time at Merck, Dr. Chodakewitz led the worldwide development and approval
activities for Crixivan^® for the treatment of HIV infection, Gardasil^® for
the prevention of cervical cancer and Zostavax^® for the prevention and
reduction in morbidity of zoster. Prior to Merck, Dr. Chodakewitz held
multiple roles in academia and was an Associate Investigator for the Veterans
Administration Medical Center, an Associate Research Scientist for the Yale
University School of Medicine and Head of the HIV Outpatient Clinic for the
Veterans Administration Medical Center in West Haven, CT. Dr. Chodakewitz
received a B.S. in Biochemistry from Yale University and his M.D. from the
Yale University School of Medicine.

About Vertex

Vertex is a global biotechnology company that aims to discover, develop and
commercialize innovative medicines so people with serious diseases can lead
better lives. Vertex scientists and our collaborators are working on new
medicines to cure or significantly advance the treatment of cystic fibrosis,
hepatitis C, rheumatoid arthritis and other life-threatening diseases. In
addition to our clinical development programs, Vertex has more than a dozen
ongoing preclinical programs aimed at other serious and life-threatening
diseases.

Founded in 1989 in Cambridge, Mass., Vertex today has research and development
sites and commercial offices in the United States, Europe, Canada and
Australia. For four years in a row, Science magazine has named Vertex one of
its Top Employers in the life sciences. For additional information and the
latest updates from the company, please visit www.vrtx.com.

Special Note Regarding Forward-Looking Statements

This press release contains forward-looking statements as defined in the
Private Securities Litigation Reform Act of 1995, including, without
limitation, the statements in the second and third paragraphs of this press
release. While Vertex believes the forward-looking statements contained in
this press release are accurate, there are a number of factors that could
cause actual events or results to differ materially from those indicated by
such forward-looking statements. Those risks and uncertainties include, among
other things, the risks listed under Risk Factors in Vertex's annual report
and quarterly reports filed with the Securities and Exchange Commission and
available through the company's website atwww.vrtx.com. Vertex disclaims any
obligation to update the information contained in this press release as new
information becomes available.

(VRTX-GEN)

Contact:

Vertex Pharmaceuticals Incorporated
Media
Zach Barber or Liz Lukegord, 617-341-6992
mediainfo@vrtx.com
or
Investors
Michael Partridge, 617-341-6108
or
Kelly Lewis, 617-961-7530
 
Press spacebar to pause and continue. Press esc to stop.